These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26513901)

  • 1. COMPARISON OF THAI GOVERNMENT MANUFACTURED TENOFOVIR (TENOFOVIR GPO300) WITH PRIVATELY MANUFACTURED TENOFOVIR (VIREAD) USED ALONG WITH LAMIVUDINE AND EFAVIRENZ TO TREAT THAI HIV PATIENTS.
    Manosuthi W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Southeast Asian J Trop Med Public Health; 2015 Jan; 46(1):19-26. PubMed ID: 26513901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.
    Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Sungkanuparph S
    J Antimicrob Chemother; 2014 Aug; 69(8):2195-201. PubMed ID: 24788661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults.
    Avihingsanon A; Maek-A-Nantawat W; Gatechompol S; Sapsirisavat V; Thiansanguankul W; Sophonphan J; Thammajaruk N; Ubolyam S; Burger DM; Ruxrungtham K
    Int J Infect Dis; 2017 Aug; 61():89-96. PubMed ID: 28627427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
    J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
    Gallant JE; Staszewski S; Pozniak AL; DeJesus E; Suleiman JM; Miller MD; Coakley DF; Lu B; Toole JJ; Cheng AK;
    JAMA; 2004 Jul; 292(2):191-201. PubMed ID: 15249568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
    Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
    HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China.
    Wu YS; Zhang WW; Ling XM; Yang L; Huang SB; Wang XC; Wu H; Cai WP; Wang M; Wang H; Liu YF; He HL; Wei FL; Wu ZY; Zhang FJ
    Chin Med J (Engl); 2016 Feb; 129(3):304-8. PubMed ID: 26831232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
    Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
    Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
    Naicker N; Naidoo A; Werner L; Garrett N; Majola N; Asari V; Baxter C; Grobler A; Karim QA; Karim SSA
    Antivir Ther; 2017; 22(4):287-293. PubMed ID: 27835613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
    Matheron S; Descamps D; Boué F; Livrozet JM; Lafeuillade A; Aquilina C; Troisvallets D; Goetschel A; Brun-Vezinet F; Mamet JP; Thiaux C;
    Antivir Ther; 2003 Apr; 8(2):163-71. PubMed ID: 12741629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview.
    Bartlett JA; Chen SS; Quinn JB
    HIV Clin Trials; 2007; 8(4):221-6. PubMed ID: 17720662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
    Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
    AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
    Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
    Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran.
    Sadeghi L; Moallemi S; Tabatabai RA; Esmaeilzadeh A; Ahsani-Nasab S; Ahmadi NE; Bayanolhagh S; Lolaie M; Narouei A; SeyedAlinaghi S; Mohraz M
    Infect Disord Drug Targets; 2018; 18(3):207-213. PubMed ID: 29308748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.